(CRDF) –
-
Form DEFA14A Cardiff Oncology, Inc.
-
Form ARS Cardiff Oncology, Inc. For: Dec 31
-
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
-
Form DEF 14A Cardiff Oncology, Inc. For: Jun 20
-
Form 8-K Cardiff Oncology, Inc. For: Apr 08
-
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
-
Form S-8 Cardiff Oncology, Inc.
-
Form 4 Cardiff Oncology, Inc. For: Mar 07 Filed by: Levine James E.
-
Form 4 Cardiff Oncology, Inc. For: Mar 07 Filed by: Kabbinavar Fairooz
-
Form 4 Cardiff Oncology, Inc. For: Mar 07 Filed by: Erlander Mark
-
Form 4 Cardiff Oncology, Inc. For: Mar 07 Filed by: Smeal Tod
-
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
-
Cardiff Oncology (CRDF) PT Raised to $14 at H.C. Wainwright
-
Cardiff Oncology (CRDF) PT Raised to $7 at Piper Sandler
-
Cardiff Oncology (CRDF) Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial
-
Cardiff Oncology, Inc. (CRDF) Misses Q4 EPS by 66c
-
Form 8-K Cardiff Oncology, Inc. For: Feb 29
-
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
-
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
-
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
-
Form 10-K Cardiff Oncology, Inc. For: Dec 31
-
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
-
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
-
Form SC 13G/A Cardiff Oncology, Inc. Filed by: ACORN BIOVENTURES, L.P.
-
Cardiff Oncology (CRDF) Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
-
Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
-
Form 8-K Cardiff Oncology, Inc. For: Jan 08
-
Form 4 Cardiff Oncology, Inc. For: Dec 19 Filed by: PACE GARY W
-
Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
-
Form 4 Cardiff Oncology, Inc. For: Nov 10 Filed by: PACE GARY W
-
Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 6c
-
Form 8-K Cardiff Oncology, Inc. For: Nov 02
-
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
-
Form 10-Q Cardiff Oncology, Inc. For: Sep 30
-
Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
-
Costco and Zions Bancorporation fall premarket; Rivian and Mattel rise
-
Form 8-K Cardiff Oncology, Inc. For: Sep 26
-
Cardiff Oncology (CRDF) Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer
-
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
-
Cardiff Oncology to Present at Upcoming Investor Conferences in September
-
Cardiff Oncology (CRDF) PT Lowered to $12 at H.C. Wainwright
-
Cardiff Oncology, Inc. (CRDF) Tops Q2 EPS by 2c
-
Form 8-K Cardiff Oncology, Inc. For: Aug 08
-
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
-
Form 10-Q Cardiff Oncology, Inc. For: Jun 30
-
Form 8-K Cardiff Oncology, Inc. For: Aug 07
-
Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
-
Form 8-K Cardiff Oncology, Inc. For: Jul 24
-
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Form 8-K Cardiff Oncology, Inc. For: Jun 20
Back to CRDF Stock Lookup
